Going viral with cancer immunotherapy

Nature Reviews Cancer

Volumn 14, Issue 8, 2014, Pages 559-567

  Lichty, Brian D ^a   Breitbach, Caroline J ^b   Stojdl, David F ^c   Bell, John C ^d,e  

^a MCMASTER UNIVERSITY   (Canada)

^b SillaJen Biotherapeutics   (United States)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CANCER VACCINE; CYCLOPHOSPHAMIDE; DIFFERENTIATION ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; H 101; HERPESVIRUS VECTOR; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; INTERLEUKIN 12; IPILIMUMAB; ONCOFETAL ANTIGEN; ONCOLYTIC VIRUS; ONCORINE; PELAREOREP; PEXASTIMOGENE DEVACIREPVEC; POXVIRUS VECTOR; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SIPULEUCEL T; SUNITINIB; TALIMOGENE LAHERPAREPVEC; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VACCINE; VIRUS VECTOR;

ADOPTIVE IMMUNOTHERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL DEATH; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEAD AND NECK CANCER; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; INFLAMMATION; LIVER CELL CARCINOMA; MELANOMA; MOLECULAR MIMICRY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; TRANSGENE; TUMOR CELL; TUMOR MICROENVIRONMENT; VESICULAR STOMATITIS VIRUS; VIRUS REPLICATION;

ANIMALS; CANCER VACCINES; GENETIC VECTORS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 84904999549     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3770     Document Type: Review

References (129)

1. Glenney, J. R. Jr., Zokas, L. & Kamps, M. P. Monoclonal antibodies to phosphotyrosine. J. Immunol. Methods 109, 277-285 (1988
2. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nature Rev. Cancer 12, 252-264 (2012
3. Kreiter, S., Castle, J. C., Tureci, O. & Sahin, U. Targeting the tumor mutanome for personalized vaccination therapy. Oncoimmunology 1, 768-769 (2012
4. Russell, S. J., Peng, K. W. & Bell, J. C. Oncolytic virotherapy. Nature Biotech. 30, 658-670 (2012
5. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646-674 (2011
6. Kelly, E. & Russell, S. J. History of oncolytic viruses: Genesis to genetic engineering. Mol. Ther. 15, 651-659 (2007 (Pubitemid 46431984)
7. Parato, K. A. et al. The oncolytic poxvirus JX 594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol. Ther. 4, 749-758 (2011
8. Stojdl, D. F. et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4, 263-275 (2003 (Pubitemid 37329791)
9. Breitbach, C. J. et al. Intravenous delivery of a multi-mechanistic cancer-Targeted oncolytic poxvirus in humans. Nature 477, 99-102 (2011
10. Liu, T. C., Hwang, T., Park, B. H., Bell, J. & Kirn, D. H. The targeted oncolytic poxvirus JX 594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol. Ther. 16, 1637-1642 (2008
11. Breitbach, C. J. et al. Oncolytic vaccinia virus disrupts tumor-Associated vasculature in humans. Cancer Res. 73, 1265-1275 (2013
12. Breitbach, C. J. et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther. 15, 1686-1693 (2007 (Pubitemid 47289013)
13. Breitbach, C. J. et al. Targeting tumor vasculature with an oncolytic virus. Mol. Ther. 19, 886-894 (2011
14. Liu, T. C., Galanis, E. & Kirn, D. Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nature Clin. Pract. Oncol. 4, 101-117 (2007 (Pubitemid 46189539)
15. Vacchelli, E. et al. Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology 2, e24612 (2013
16. Miest, T. S. & Cattaneo, R. New viruses for cancer therapy: Meeting clinical needs. Nature Rev. Microbiol. 12, 23-34 (2013
17. Atherton, M. J. & Lichty, B. D. Evolution of oncolytic viruses: Novel strategies for cancer treatment. Immunotherapy 5, 1191-1206 (2013
18. Kaufman, H. L. & Bines, S. D. OPTIM trial: A Phase III trial of an oncolytic herpes virus encoding GM CSF for unresectable stage III or IV melanoma. Future Oncol. 6, 941-949 (2010
19. Garber, K. China approves worlds first oncolytic virus therapy for cancer treatment. J. Natl Cancer Inst. 98, 298-300 (2006
20. Senzer, N. N. et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 27, 5763-5771 (2009
21. Nemunaitis, J. et al. Intravenous infusion of a replication-selective adenovirus (ONYX 015) in cancer patients: Safety, feasibility and biological activity. Gene Ther. 8, 746-759 (2001 (Pubitemid 32509788)
22. Park, B. H. et al. Use of a targeted oncolytic poxvirus, JX 594, in patients with refractory primary or metastatic liver cancer: A phase I trial. Lancet Oncol. 9, 533-542 (2008
23. Heo, J. et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX 594 in liver cancer. Nature Med. 19, 329-336 (2013
24. Ingemar Andtbacka, R. H. et al. OPTiM: A randomized phase III trial of talimogene laherparepvec (T VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM CSF) for the treatment (tx) of unresected stage IIIB/C & IV melanoma. J. Clin. Oncol. 31, abstract LBA9008 (2013
25. Harrington, K. J. et al. Phase I/II study of oncolytic HSV GM CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin. Cancer Res. 16, 4005-4015 (2010
26. Harrington, K. J. et al. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin. Cancer Res. 16, 3067-3077 (2010
27. Heo, J. et al. Sequential therapy with JX 594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: Preclinical and clinical demonstration of combination efficacy. Mol. Ther. 19, 1170-1179 (2011
28. Cerullo, V. et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol. Ther. 19, 1737-1746 (2011
29. Kantoff, P. W. et al. Sipuleucel T immunotherapy for castration-resistant prostate cancer. New Engl. J. Med. 363, 411-422 (2010
30. Small, E. J. et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24, 3089-3094 (2006 (Pubitemid 46638945)
31. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl. J. Med. 363, 711-723 (2010
32. Qureshi, O. S. et al. Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA 4. Science 332, 600-603 (2011
33. Dudley, M. E. & Rosenberg, S. A. Adoptive-cell-Transfer therapy for the treatment of patients with cancer. Nature Rev. Cancer 3, 666-675 (2003 (Pubitemid 37328821)
34. Kershaw, M. H., Westwood, J. A. & Darcy, P. K. Gene-engineered T cells for cancer therapy. Nature Rev. Cancer 13, 525-541 (2013
35. Adair, R. A. et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci. Transl. Med. 4, 138ra77 (2012
36. Kottke, T. et al. Treg depletion-enhanced IL 2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol. Ther. 16, 1217-1226 (2008 (Pubitemid 351866052)
37. Diaz, R. M. et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res. 67, 2840-2848 (2007 (Pubitemid 46548974)
38. Liu, B. L. et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-Tumour properties. Gene Ther. 10, 292-303 (2003 (Pubitemid 36305598)
39. Moehler, M. H. et al. Parvovirus H-1 induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum. Gene Ther. 16, 996-1005 (2005 (Pubitemid 41153868)
40. Mastrangelo, M. J. et al. Intratumoral recombinant GM CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 6, 409-422 (1999 (Pubitemid 129667814)
41. Hwang, T. H. et al. A mechanistic proof of concept clinical trial with JX 594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol. Ther.19, 1913-1922 (2011
42. Kim, M. K. et al. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci. Transl. Med. 5, 185ra63 (2013
43. Sukkurwala, A. Q. et al. Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. Cell Death Differ. 21, 59-68 (2014
44. Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL 1beta dependent adaptive immunity against tumors. Nature Med. 15, 1170-1178 (2009
45. Zelenay, S. et al. The dendritic cell receptor DNGR 1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice. J. Clin. Invest. 122, 1615-1627 (2012
46. Lee, B. H. et al. Activation of P2X(7) receptor by ATP plays an important role in regulating inflammatory responses during acute viral infection. PLoS ONE 7, e35812 (2012
47. Huang, B., Sikorski, R., Kirn, D. H. & Thorne, S. H. Synergistic anti-Tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. Gene Ther. 18, 164-172 (2011
48. Miyamoto, S. et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res. 72, 2609-2621 (2012
49. Postow, M. A. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925-931 (2012
50. Galivo, F. et al. Interference of CD40L mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum. Gene Ther. 21, 439-450 (2010
51. Schirrmacher, V., Griesbach, A. & Ahlert, T. Antitumor effects of Newcastle disease virus in vivo: Local versus systemic effects. Int. J. Oncol. 18, 945-952 (2001
52. Diallo, J. S. et al. A high-Throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol. Ther. 18, 1123-1129 (2010
53. Nguyen, T. L. et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc. Natl Acad. Sci. USA 105, 14981-14986 (2008
54. Jha, B. K., Dong, B., Nguyen, C. T., Polyakova, I. & Silverman, R. H. Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy. Mol. Ther. 21, 1749-1757 (2013
55. Bose, A. et al. Sunitinib facilitates the activation and recruitment of therapeutic anti-Tumor immunity in concert with specific vaccination. Int. J. Cancer 129, 2158-2170 (2011
56. Beug, S. T. et al. Smac mimetics and innate immune stimuli synergize to promote tumor death. Nature Biotech. 32, 182-190 (2014
57. Hu, J. C. et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 12, 6737-6747 (2006 (Pubitemid 44876843)
58. Curran, M. A. & Allison, J. P. Tumor vaccines expressing flt3 ligand synergize with ctla 4 blockade to reject preimplanted tumors. Cancer Res. 69, 7747-7755 (2009
59. Epardaud, M. et al. Interleukin 15/interleukin 15Rα complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res. 68, 2972-2983 (2008 (Pubitemid 351556298)
60. Liu, R. B. et al. IL 15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner. Proc. Natl Acad. Sci. USA 110, 8158-8163 (2013
61. Onu, A., Pohl, T., Krause, H. & Bulfone-Paus, S. Regulation of IL 15 secretion via the leader peptide of two IL 15 isoforms. J. Immunol. 158, 255-262 (1997 (Pubitemid 127483863)
62. Yu, F. et al. T cell engager-Armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol. Ther. 22, 102-111 (2014
63. Amato, R. J. et al. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: A phase II trial. Clin. Cancer Res. 14, 7504-7510 (2008
64. Harrop, R. et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: A phase I/II trial. Clin. Cancer Res. 12, 3416-3424 (2006
65. Horig, H. et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co stimulatory molecule. Cancer Immunol. Immunother. 49, 504-514 (2000
66. Jager, E. et al. Recombinant vaccinia/fowlpox NY ESO 1 vaccines induce both humoral and cellular NY ESO 1 specific immune responses in cancer patients. Proc. Natl Acad. Sci. USA 103, 14453-14458 (2006 (Pubitemid 44484771)
67. Kaufman, H. L. et al. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin. Cancer Res. 14, 4843-4849 (2008
68. Madan, R. A. et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial. Lancet Oncol. 13, 501-508 (2012
69. Morse, M. A. et al. Novel adenoviral vector induces T cell responses despite anti-Adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol. Immunother. 62, 1293-1301 (2013
70. Odunsi, K. et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY ESO 1 antigen in ovarian cancer and melanoma patients. Proc. Natl Acad. Sci. USA 109, 5797-5802 (2012
71. Harrop, R., John, J. & Carroll, M. W. Recombinant viral vectors: Cancer vaccines. Adv. Drug Deliv. Rev. 58, 931-947 (2006 (Pubitemid 44709263)
72. Elzey, B. D., Siemens, D. R., Ratliff, T. L. & Lubaroff, D. M. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int. J. Cancer 94, 842-849 (2001 (Pubitemid 33032833)
73. Hodge, J. W., McLaughlin, J. P., Kantor, J. A. & Schlom, J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T cell immunity and antitumor responses. Vaccine 15, 759-768 (1997 (Pubitemid 27240492)
74. Hodge, J. W. et al. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res. 63, 7942-7949 (2003 (Pubitemid 37466731)
75. Irvine, K. R. et al. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J. Natl Cancer Inst. 89, 1595-1601 (1997 (Pubitemid 27479719)
76. Marshall, J. L. et al. Phase I study in advanced cancer patients of a diversified prime-And-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti- carcinoembryonic antigen immune responses. J. Clin. Oncol. 18, 3964-3973 (2000
77. Naslund, T. I. et al. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor. J. Immunol. 178, 6761-6769 (2007 (Pubitemid 46847400)
78. Bridle, B. W. et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol. Ther. 18, 1430-1439 (2010
79. Vigil, A., Martinez, O., Chua, M. A. & Garcia-Sastre, A. Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol. Ther. 16, 1883-1890 (2008
80. Pol, J. G. et al. Maraba virus as a potent oncolytic vaccine vector. Mol. Ther. 22, 420-429 (2014
81. Loi, S. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. Oncoimmunology 2, e24720 (2013
82. Zamarin, D. et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 6, 226ra32 (2014
83. Puzanov, I. et al. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin. Oncol. 32 (suppl; abstr 9029) (2014
84. Pule, M. A. et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nature Med. 14, 1264-1270 (2008
85. Martins, I. et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 30, 1147-1158 (2011
86. Galluzzi, L. & Kroemer, G. Autophagy mediates the metabolic benefits of endurance training. Circ. Res. 110, 1276-1278 (2012
87. Kaczmarek, A., Vandenabeele, P. & Krysko, D. V. Necroptosis: The release of damage-Associated molecular patterns and its physiological relevance. Immunity 38, 209-223 (2013
88. Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nature Rev. Cancer 12, 860-875 (2012
89. Kaufman, H. L. et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM CSF in patients with stage IIIc and IV melanoma. Ann. Surg. Oncol. 17, 718-730 (2010
90. Kim, J. H. et al. Systemic armed oncolytic and immunologic therapy for cancer with JX 594, a targeted poxvirus expressing GM CSF. Mol. Ther. 14, 361-370 (2006 (Pubitemid 44184970)
91. Lee, J. H. et al. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther. 17, 73-79 (2010
92. Cerullo, V. et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res. 70, 4297-4309 (2010
93. Chang, J. et al. A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: Armed oncolytic adenovirus for the treatment of head and neck cancers. Cancer Biol. Ther. 8, 676-682 (2009
94. Robinson, M. et al. Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors. J. Virol. 83, 3450-3462 (2009
95. Vigil, A. et al. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. 67, 8285-8292 (2007 (Pubitemid 47395166)
96. Grote, D., Cattaneo, R. & Fielding, A. K. Neutrophils contribute to the measles virus-induced antitumor effect: Enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res. 63, 6463-6468 (2003 (Pubitemid 37255198)
97. Bergman, I., Griffin, J. A., Gao, Y. & Whitaker-Dowling, P. Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu. Int. J. Cancer 121, 425-430 (2007 (Pubitemid 46917713)
98. Bernt, K. M., Ni, S., Tieu, A. T. & Lieber, A. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Cancer Res. 65, 4343-4352 (2005 (Pubitemid 40775673)
99. Ramakrishna, E. et al. Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. Cancer Res. 69, 1448-1458 (2009
100. Leveille, S., Goulet, M. L., Lichty, B. D. & Hiscott, J. Vesicular stomatitis virus oncolytic treatment interferes with tumor-Associated dendritic cell functions and abrogates tumor antigen presentation. J. Virol. 85, 12160-12169 (2011
101. Lapteva, N. et al. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J. Immunother. 32, 145-156 (2009
102. Li, J. et al. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol. Ther. 19, 650-657 (2011
103. Carew, J. F. et al. A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes. Mol. Ther. 4, 250-256 (2001 (Pubitemid 32851289)
104. Zhao, H., Janke, M., Fournier, P. & Schirrmacher, V. Recombinant Newcastle disease virus expressing human interleukin 2 serves as a potential candidate for tumor therapy. Virus Res. 136, 75-80 (2008
105. Post, D. E. et al. Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin 4. Cancer Res. 67, 6872-6881 (2007 (Pubitemid 47105534)
106. Terada, K., Wakimoto, H., Tyminski, E., Chiocca, E. A. & Saeki, Y. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther. 13, 705-714 (2006
107. Choi, I. K. et al. Oncolytic adenovirus co expressing IL 12 and IL 18 improves tumor-specific immunity via differentiation of T cells expressing IL 12Rβ2 or IL 18Rα. Gene Ther. 18, 898-909 (2011
108. Lee, Y. S. et al. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin 12 and B7 1 in an immunocompetent murine model. Clin. Cancer Res. 12, 5859-5868 (2006
109. Derubertis, B. G. et al. Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T cell-dependent mechanisms. Cancer Gene Ther. 14, 590-597 (2007
110. Varghese, S. et al. Enhanced therapeutic efficacy of IL 12, but not GM CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther. 13, 253-265 (2006 (Pubitemid 43255762)
111. Shin, E. J. et al. Interleukin 12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma. Laryngoscope 117, 210-214 (2007 (Pubitemid 46207874)
112. Gaston, D. C. et al. Production of bioactive soluble interleukin 15 in complex with interleukin 15 receptor alpha from a conditionally-replicating oncolytic HSV 1. PLoS ONE 8, e81768 (2013
113. Stephenson, K. B., Barra, N. G., Davies, E., Ashkar, A. A. & Lichty, B. D. Expressing human interleukin 15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-Tumor immunity. Cancer Gene Ther. 19, 238-246 (2012
114. Van Rikxoort, M. et al. Oncolytic effects of a novel influenza A virus expressing interleukin 15 from the NS reading frame. PLoS ONE 7, e36506 (2012
115. Fukuhara, H., Ino, Y., Kuroda, T., Martuza, R. L. & Todo, T. Triple gene-deleted oncolytic herpes simplex virus vector double-Armed with interleukin 18 and soluble B7 1 constructed by bacterial artificial chromosome-mediated system. Cancer Res. 65, 10663-10668 (2005 (Pubitemid 41713331)
116. Ino, Y., Saeki, Y., Fukuhara, H. & Todo, T. Triple combination of oncolytic herpes simplex virus 1 vectors armed with interleukin 12, interleukin 18, or soluble B7 1 results in enhanced antitumor efficacy. Clin. Cancer Res. 12, 643-652 (2006 (Pubitemid 43166160)
117. Kirn, D. H., Wang, Y., Le Boeuf, F., Bell, J. & Thorne, S. H. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med. 4, e353 (2007
118. Li, H., Peng, K. W., Dingli, D., Kratzke, R. A. & Russell, S. J. Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther. 17, 550-558 (2010
119. Shashkova, E. V., Spencer, J. F., Wold, W. S. & Doronin, K. Targeting interferon-α increases antitumor efficacy and reduces hepatotoxicity of E1A mutated spread-enhanced oncolytic adenovirus. Mol. Ther. 15, 598-607 (2007
120. Shashkova, E. V., Kuppuswamy, M. N., Wold, W. S. & Doronin, K. Anticancer activity of oncolytic adenovirus vector armed with IFN-α and ADP is enhanced by pharmacologically controlled expression of TRAIL. Cancer Gene Ther. 15, 61-72 (2008
121. Willmon, C. L. et al. Expression of IFN-β enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res. 69, 7713-7720 (2009
122. Su, C. et al. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-γ gene yields efficient antitumor activity in immunodeficient and immunocompetent mice. Mol. Ther. 13, 918-927 (2006
123. Choi, K. J. et al. Concurrent delivery of GM CSF and B7 1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther. 13, 1010-1020 (2006
124. Todo, T., Martuza, R. L., Dallman, M. J. & Rabkin, S. D. In situ expression of soluble B7 1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res. 61, 153-161 (2001 (Pubitemid 32095713)
125. Huang, J. H. et al. Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL 12 and 4 1BBL. Mol. Ther. 18, 264-274 (2010
126. Kim, H. S., Kim-Schulze, S., Kim, D. W. & Kaufman, H. L. Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4 1BB ligand. Cancer Res. 69, 8516-8525 (2009
127. Li, J. L. et al. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Ther. 16, 376-382 (2009
128. Yoo, J. Y. et al. Tumor suppression by apoptotic and anti-Angiogenic effects of mortalin-Targeting adeno-oncolytic virus. J. Gene Med. 12, 586-595 (2010
129. Hu, Z. B. et al. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes. Cancer Gene Ther. 15, 173-182 (2008